Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007

Health Affairs

Volumn 34, Issue 4, 2015, Pages 562-570

  Stevens, Warren ^a   Philipson, Tomas J ^b   Khan, Zeba M ^c   MacEwan, Joanna P ^a   Linthicum, Mark T ^a   Goldman, Dana P ^d  

^a PRECISION HEALTH ECONOMICS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c CELGENE CORPORATION   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; ECONOMICS; HEALTH; HEALTH CARE DELIVERY; MORTALITY; NEOPLASM; STATISTICS AND NUMERICAL DATA; TRENDS;

DELIVERY OF HEALTH CARE; GLOBAL HEALTH; HEALTH EXPENDITURES; HUMANS; MORTALITY; NEOPLASMS;

EID: 84929617334     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0634     Document Type: Article

References (42)

1. Reinhardt UE, Hussey PS, Anderson GF. U.S. health care spending in an international context. Health Aff (Millwood). 2004;23(3):10-25.
2. Anderson GF, Frogner BK, Reinhardt UE. Health spending in OECD countries in 2004: an update. Health Aff (Millwood). 2007;26(5):1481-9.
3. Kanavos P, Ferrario A, Vandoros S, Anderson GF. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood). 2013;32(4):753-61.
4. Laugesen MJ, Glied SA. Higher fees paid to US physicians drive higher spending for physician services compared to other countries. Health Aff (Millwood). 2011;30(9):1647-56.
5. Thorpe KE, Howard DH, Galactionova K. Differences in disease prevalence as a source of the U.S.-European health care spending gap. Health Aff (Millwood). 2007; 26(6):w678-86. DOI: 10.1377/ hlthaff.26.6.w678.
6. Squires DA. Explaining high health care spending in the United States:an international comparison of supply, utilization, prices, and quality [Internet]. New York (NY):Commonwealth Fund; 2012 May [cited 2015 Feb 4]. Available from:http://www.commonwealthfund .org/~/media/files/publications/ issue-brief/2012/may/1595_ squires_explaining_high_hlt_care_ spending_intl_brief.pdf
7. Nolte E, McKee CM. In amenable mortality-deaths avoidable through health care-progress in the US lags that of three European countries. Health Aff (Millwood). 2012;31(9):2114-22.
8. Bezruchka S. The hurrider I go the behinder I get: the deteriorating international ranking of U.S. health status. Annu Rev Public Health. 2012;33(1):157-73.
9. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-42.
10. Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer. 2009; 45(7):1188-92.
11. Degrassat-Théas A, Bensadon M, Rieu C, Angalakuditi M, Le Pen C, Paubel P. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures. Pharmacoeconomics. 2012;30(7):565-73.
12. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents:a worldwide populationbased study (CONCORD). Lancet Oncol. 2008;9(8):730-56.
13. Lenner P. The excess mortality rate. A useful concept in cancer epidemiology. Acta Oncol. 1990;29(5):573-6.
14. Brawley OW. Prostate cancer epidemiology in the United States.World J Urol. 2012;30(2):195-200.
15. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260(2):103-17.
16. Thompson IM, Canby-Hagino E, Lucia MS. Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst. 2005;97(17):1236-7.
17. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst. 2010; 102(9):605-13.
18. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604-8.
19. Nolte E, McKee M. Does health care save lives? Avoidable mortality revisited [Internet]. London: Nuffield Trust; 2004 [cited 2015 Feb 4]. Available from: http://www.nuffield trust.org.uk/sites/files/nuffield/ publication/does-healthcare-savelives- mar04.pdf
20. Mackenbach JP, Bouvier-Colle MH, Jougla E. "Avoidable" mortality and health services: a review of aggregate data studies. J Epidemiol Community Health. 1990;44(2):106-11.
21. Nolte E, McKee CM. Measuring the health of nations: updating an earlier analysis. Health Aff (Millwood). 2008;27(1):58-71.
22. To access the Appendix, click on the Appendix link in the box to the right of the article online.
23. World Health Organization. WHO Mortality Database [Internet]. Geneva: WHO; 2013 [cited 2015 Feb 18]. Available from: http:// www.who.int/healthinfo/mortality_ data/en/
24. European Cancer Observatory [home page on the Internet]. Lyon (France): The Observatory; c 2012 [cited 2015 Feb 4]. Available from:http://eco.iarc.fr
25. World Health Organization. Health accounts: Global Health Expenditure Database [Internet]. Geneva: WHO; [cited 2015 Feb 4]. Available from:http://www.who.int/healthaccounts/ ghed/en/
26. Jonsson B, Wilking N. The burden and cost of cancer. Ann Oncol. 2007;18(Suppl 3):ii8-22.
27. Australian Institute of Health and Welfare. Health system expenditure on cancer and other neoplasms in Australia, 2008-09 [Internet]. Canberra: The Institute; 2013 [cited 2015 Feb 4]. (Cancer Series No. 81). Available from: http://www.aihw .gov.au/WorkArea/DownloadAsset .aspx?id=60129545609
28. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165-74.
29. Kalseth J, Halvorsen T, Kalseth B, Sarheim Anthun K, Peltola M, Kautiainen K, et al. Cross-country comparisons of health care costs: the case of cancer treatment in the Nordic countries. Health Policy. 2014;115(2-3):172-9.
30. Desai M, Nolte E, Karanikolos M, Khoshaba B, McKee M. Measuring NHS performance 1990-2009 using amenable mortality: interpret with care. J R Soc Med. 2011;104(9):370-9.
31. National Cancer Institute. Surveillance, Epidemiology, and End Results Program: standard populations (millions) for age-adjustment [Internet]. Bethesda (MD): NCI; [cited 2015 Feb 5]. Available from: http:// seer.cancer.gov/stdpopulations/
32. Gay JG, Paris V, Devaux M, de Looper M. Mortality amenable to health care in 31 OECD countries:estimates and methodological issues [Internet]. Paris: Organization for Economic Cooperation and Development; 2011 Jan 31 [cited 2015 Feb 4]. (OECD Health Working Paper No. 55). Available from: http:// www.oecd.org/officialdocuments/ publicdisplaydocumentpdf/?cote= DELSA/HEA/WD/HWP(2011)1&doc Language=En
33. Coleman MP. Trends in breast cancer incidence, survival, and mortality. Lancet. 2000;356(9229):590-1.
34. Statistical smoothing is used simply to take out the kinks in irregular data. The results are not affected, but year-on-year fluctuations are smoothed out to highlight the underlying trend.
35. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012 [Internet]. Lyon (France): IARC; [cited 2015 Feb 5]. Available from:http://globocan.iarc.fr/Default.aspx
36. Dekimpe MG, Parker PM, Sarvary M. "Globalization": modeling technology adoption timing across countries. Technology Forecasting and Social Change. 2000;63(1):25-42.
37. Beise M. Lead markets: countryspecific drivers of the global diffusion of innovations. Res Policy. 2004;33(6-7):997-1018.
38. Gardner CA, Acharya T, Yach D. Technological and social innovation:a unifying new paradigm for global health. Health Aff (Millwood). 2007;26(4):1052-61.
39. Remák E, Hutton J, Jones M, Zagari M. Changes in cost-effectiveness over time. The case of Epoetin Alfa for renal replacement therapy patients in the UK. Eur J Health Econ. 2003;4(2):115-21.
40. Jena AB, Philipson TJ. Endogenous cost-effectiveness analysis and health care technology adoption. J Health Econ. 2013;32(1):172-80.
41. Stevens W, Normand C. Optimisation versus certainty: understanding the issue of heterogeneity in economic evaluation. Soc Sci Med. 2004;58(2):315-20.
42. O'Mahony JF, van Rosmalen J, Zauber AG, van Ballegooijen M. Multicohort models in cost-effectiveness analysis why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making. 2013;33(3):407-14.